Hi friends!!!
In our previous blog, we have discussed about the following topics.
EU MDR Timeline, Annex, Chapter
EU MDR Post Market Surveillance
EU MDR Technical Documentation - Part 1
EU MDR Technical Documentation - Part 2
EU MDR General Safety and Performance Requirement
EU MDR Information on the Label
EU MDR 2017/745 is live now. And it the most trending topic in Medical Device Regulatory Affairs field. Most of the medical device companies are in EU MDR Transition to make sure that they can sell their products in Europe.
Therefore, it is important for Medical Device QA/RA Professionals to know in detail about EU MDR 2017/745 requirements for Post Market Clinical Follow Up.
Let’s discuss in detail about the Post Market Clinical Follow Up as per EU MDR 2017/745.
Image courtesy: WikipediaLicensed under: CC Share Alike
POST MARKET CLINICAL FOLLOW UP
In EU MDR 2017/745, Annex
XIV Part B talks about Post Market Clinical Follow up.
PMCF shall be understood
to be a continuous process that updates the clinical evaluation referred to in
Article 61 and Part A of Annex XIV and shall be addressed in the manufacturer's
post-market surveillance plan. When conducting PMCF, the manufacturer shall
proactively collect and evaluate clinical data from the use in or on humans of
a device which bears the CE marking and is placed on the market or put into
service within its intended purpose as referred to in the relevant conformity
assessment procedure, with the aim of confirming the safety and performance
throughout the expected lifetime of the device, of ensuring the continued
acceptability of identified risks and of detecting emerging risks on the basis
of factual evidence.
POST MARKET CLINICAL FOLLOW UP
PLAN
1. PMCF shall be performed
pursuant to a documented method laid down in a PMCF plan.
1.1 The PMCF plan shall
specify the methods and procedures for proactively collecting and evaluating
clinical data as following.
(a) Confirming the safety
and performance of the device throughout its expected lifetime.
(b) Identifying
previously unknown side-effects and monitoring the identified side-effects and
contraindications.
(c) Identifying and
analyzing emergent risks on the basis of factual evidence.
(d) Ensuring the
continued acceptability of the benefit-risk ratio referred to in Sections 1 and
9 of Annex I.
(e) Identifying possible
systematic misuse or off-label use of the device, with a view to verifying that
the intended purpose is correct.
1.2 The PMCF plan shall
include at least the following.
(a) The general methods
and procedures of the PMCF to be applied, such as gathering of clinical
experience gained, feedback from users, screening of scientific literature and
of other sources of clinical data.
(b) The specific methods
and procedures of PMCF to be applied, such as evaluation of suitable registers
or PMCF studies.
(c) A rationale for the
appropriateness of the methods and procedures referred to in points (a) and (b).
(d) A reference to the
relevant parts of the clinical evaluation report referred to in Section 4 and
to the risk management referred to in Section 3 of Annex I.
(e) The specific
objectives to be addressed by the PMCF.
(f) An evaluation of the
clinical data relating to equivalent or similar devices.
(g) Reference to any
relevant CS, harmonized standards when used by the manufacturer, and relevant
guidance on PMCF.
(h) A detailed and
adequately justified time schedule for PMCF activities (e.g. analysis of PMCF
data and reporting) to be undertaken by the manufacturer.
2. The manufacturer shall
analyze the findings of the PMCF and document the results in a PMCF evaluation
report that shall be part of the clinical evaluation report and the technical
documentation.
3. The conclusions of the
PMCF evaluation report shall be taken into account for the clinical evaluation
referred to in Article 61 and Part A of this Annex and in the risk management
referred to in Section 3 of Annex I. If, through the PMCF, the need for
preventive and/or corrective measures has been identified, the manufacturer
shall implement them.
Now I hope you have acquired some knowledge about EU MDR 2017/745 requirements for Post Market Clinical Follow Up. We will meet again with another valuable topic related to Biomedical Engineering, Medical Device, Healthcare.
NOTE: Dear friends!!!... Please do comment a topic related to Biomedical, so that we can discuss it in future blogs.
Check out for this blog about Computed Tomography, X ray, MRI scan, ECG.
COMPUTED TOMOGRAPHY|TECHNOLOGY|ARTIFACTS
x ray machine working principle
DON’T FORGET TO FOLLOW THIS BLOG PAGE
DROP YOUR MAIL ID TO GET IMMEDIATE UPDATES
If you find this blog post knowledgeable,
comment & share it with a friend!
No comments:
Post a Comment